Colleen Elizabeth Annesley, MD

Colleen Elizabeth Annesley, MD

Cancer and Blood Disorders Center, Leukemia and Lymphoma Program, Apheresis, Immunotherapy Program, Oncology

On staff since September 2015

Children's Title: Medical Director and interim co-Chief Medical Officer, Seattle Children's Therapeutics

Academic Title: Associate Professor, Department of Pediatrics, University of Washington School of Medicine

Research Center: Ben Towne Center for Childhood Cancer Research

"It is inspiring and humbling to work with children, young adults and families in their battle against pediatric cancer. Their bravery and perseverance are the driving force behind finding tomorrow's cure."

  • Colleen Annesley, MD, is an attending physician at Seattle Children's Hospital, and an assistant professor in the Department of Pediatrics at the University of Washington. Her clinical areas of interest are leukemia, lymphoma, and high risk or relapsed leukemia.

    My research interests include the development of novel immunotherapy trials for the treatment of pediatric leukemia and lymphoma. CAR T cell immunotherapy has been a ground-breaking treatment for these diseases, and we are now working to improve upon this therapy even further, with the goal of providing a lasting cure for all children with this disease.

    • Kayli Boise, ID 05.08.18

      I am now a 15 year old and had Dr. Annesley treat my B-Cell Lymphoma cancer. She was AMAZING!! She is so understanding about anything that is going on and tries to help you in any way that she can. When my parents or I had any questions about my treatment she would answer them in detail so we knew what was going on. Dr. Annesley is one of the best doctors I've ever had. She was so accommodating and if I had a choice in my treatment she would always give it to me. As a teenager going through cancer treatment it's comforting to know that she is super precise and that I was in good hands. She made a plan to cure my cancer and succeeded and she will always be one of my greatest heroes.

    • Alison Bellevue, WA 10.03.17

      Dr. Annesley is a wonderful physician - very knowledgeable,caring, and compassionate! She treated our son for HLH recently. She is a very good communicator and took time to answer questions and address our concerns. We are very happy with the care we received from Dr. Annesley and the entire Hem/Onc clinic!

    • Sammantha Orting, WA 08.23.17

      Dr. Annesley is the BEST! Our son Grayson is currently receiving treatment at Seattle Childrens for Leukemia and she is his doctor. She is very smart and walks us through every lab test, chemotherapy dosage, listens to us and answers all of our questions respectfully. She never acts like shes in too big of a hurry to bother with us like our last doctors and is always super sweet to us and especially Grayson. I have seen a huge change in him since coming to Seattle a few months ago. He was very shy and very nervous around our last doctors and it was heartbreaking. You can tell he truly adores her and trusts her and that makes our hearts so happy! We would move to Africa if that's where she was! Best doctor ever!!!

    • Steve Wake Forest, North Carolina 07.28.17

      We came to Seattle for the PLAT 02 trial for my 15 year old son. Dr. Annesley was his primary physician during our time here. She. Is. Amazing. She seemed to be ever-present. She was patient with our every question. She treated Harrison and our entire family with respect and understanding. Dr. Annesley took the time to explain every aspect of the trial and treatment to Harrison. I never once questioned her sincere commitment to his well-being. Harrison thinks of her as a friend as much as a doctor. She combines a brilliant mind with a brilliant personality. In almost six years of cancer treatment we have met dozens of pediatric oncologists. Every family forced into the childhood cancer community would want one like Dr. Colleen Annesley. She is hero.

  • Award Name Award Description Awarded By Award Date
    Recipient, National Institutes of Health Extramural Loan Repayment Program 2013 - 2016
    Selected Participant, AACR Workshop: Molecular Biology in Clinical Oncology 2013
    Department of Pediatrics Teaching Excellence Award University of Miami and Jackson Memorial Hospital 2007
  • Other Publications

    • Annesley CE, Summers C, Ceppi F, Gardner RA
      The Evolution and Future of CAR T Cells for B-Cell Acute Lymphoblastic Leukemia.
      29171004 Clinical pharmacology and therapeutics, 2018 April : 103(4)591-598
    • Ceppi F, Rivers J, Annesley C, Pinto N, Park JR, Lindgren C, Mgebroff S, Linn N, Delaney M, Gardner RA
      Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma.
      29536556 Transfusion, 2018 Mar 13
    • Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, Bleakley M, Brown C, Mgebroff S, Kelly-Spratt KS, Hoglund V, Lindgren C, Oron AP, Li D, Riddell SR, Park JR, Jensen MC
      Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.
      28408462 Blood, 2017 Jun 22 : 129(25)3322-3331 PMCID:PMC5482103
    • Cooper TM, Cassar J, Eckroth E, Malvar J, Sposto R, Gaynon P, Chang BH, Gore L, August K, Pollard JA, DuBois SG, Silverman LB, Oesterheld J, Gammon G, Magoon D, Annesley C, Brown PA
      A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia andamp; Lymphoma (TACL) Study.
      26920889 Clinical cancer research : an official journal of the American Association for Cancer Research, 2016 Aug 15 : 22(16)4014-22
    • Sison EA, Magoon D, Li L, Annesley CE, Romagnoli B, Douglas GJ, Tuffin G, Zimmermann J, Brown P
      POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL.
      26360610 Oncotarget, 2015 Oct 13 : 6(31)30902-18 PMCID:PMC4741576
    • Annesley CE, Brown P
      Novel agents for the treatment of childhood acute leukemia.
      25830014 Therapeutic advances in hematology, 2015 April : 6(2)61-79 PMCID:PMC4365053
    • Sison EA, Magoon D, Li L, Annesley CE, Rau RE, Small D, Brown P
      Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition.
      25333254 Oncotarget, 2014 Oct 15 : 5(19)8947-58 PMCID:PMC4253409
    • Rau R, Magoon D, Greenblatt S, Li L, Annesley C, Duffield AS, Huso D, McIntyre E, Clohessy JG, Reschke M, Pandolfi PP, Small D, Brown P
      NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease.
      24184354 Experimental hematology, 2014 Feb. : 42(2)101-13.e5 PMCID:PMC3932758
    • Annesley CE, Brown P
      The Biology and Targeting of FLT3 in Pediatric Leukemia.
      25295230 Frontiers in oncology, 2014 : 4263 PMCID:PMC4172015
  • Presentations Title Event Location Date
    Wilms tumor 1 (WT1) Mutations Impair Myeloid Differentiation and Cause Myelodysplasia in a Mouse Model". Third Workshop on WT1 Biology Edinburgh, United Kingdom June 2015
    Pediatric Immunotherapy CAR T cells Pediatric Cancer Care: Implications for the Continuum of Rehabilitation Seattle Childrens Hospital Sept. 2017
    Wilms tumor 1 (WT1) Mutations Impair Myeloid Differentiation and Cause Myelodysplasia in a Mouse Model NCI Pediatric Oncology Branch, Research Seminar Series Bethesda, MD Feb. 2015
  • Grant Title Grantor Amount Award Date
    Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-03: A Pilot Feasibility and Safety Study of CD19t T-Antigen Presenting Cells (T-APCs) Following CAR T Cell Immunotherapy for CD19+ Leukemia Clinical Research Scholar Program $140,000.00 Oct 1, 2017 - Sep 30, 2019
    Elucidating the Functional Role of WT1 mutations in leukemogenesis St. Baldricks Foundation $241,392.00 Jul 1, 2012 - Jun 30, 2015


Board Certification(s)

Pediatric Hematology-Oncology

Medical/Professional School

Temple University School of Medicine, Philadelphia, PA


University of Miami Emergency Medicine Residency, Miami, FL


Johns Hopkins University School of Medicine, Baltimore, MD

Research Focus Area

Cardiotoxicity prevention & prediction